INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

INVESTED is a randomized, double-blind, multicenter trial to assess the cardiopulmonary benefit of high dose comparted with standard dose influenza vaccine in a high-risk cardiovascular population.  Potential subjects must have a history of Myocardial infarction in the previous 12 months OR history of heart failure hospitalization in the previous 24 months.  Subjects will be randomized in a 1:1 ratio to high dose or standard dose.  Total trial duration is 5 years including site initiation, a Vanguard season followed by 3 influenza seasons, and follow up until the end of the last influenza recruiting season.

PI: Dr. Geoffrey Gorse

Study Coordinator: Peggy Donovan

This study is now closed to enrollment.